Tofersen
Brand names: Qalsody · Active ingredient: Tofersen
In short: QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with
What is Tofersen used for?
QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
Tofersen dosage
Recommended Dosage
Administer QALSODY intrathecally using a lumbar puncture by, or under the direction of, healthcare professionals experienced in performing lumbar punctures.
The recommended dosage is 100 mg (15 mL) of QALSODY per administration.
Initiate QALSODY treatment with three (3) loading doses administered at 14-day intervals.
Administer a maintenance dose every 28 days thereafter.
Missed Dose
If the second loading dose is missed, administer QALSODY as soon as possible, and administer the third loading dose 14 days later.
If the third loading dose or a maintenance dose is missed, administer QALSODY as soon as possible, and administer the next dose 28 days later.
Use aseptic technique when preparing and administering QALSODY intrathecally. Prepare and administer QALSODY according to the following steps:
Preparation
Vial preparation instructions
Allow refrigerated QALSODY vial to warm to room temperature (25°C/77°F) prior to administration without using external heat sources .
Inspect the solution in the QALSODY vial prior to administration. Do not administer if particles are observed or the liquid in the vial is not clear and colorless to slightly yellow.
Do not shake the QALSODY vial.
Procedural preparation instructions
If indicated by the clinical condition of the patient, consider sedation.
If indicated by the clinical condition of the patient, consider imaging to guide intrathecal administration of QALSODY.
Prior to removing the vial's cap on the aluminum overseal, confirm readiness of the patient. An unopened QALSODY vial can be returned to the refrigerator .
Evaluate patients prior to and after intrathecal injection for the presence of potential conditions related to lumbar puncture, to avoid serious procedural complications.
Administration
Prior to administration, remove approximately 10 mL of cerebrospinal fluid (CSF) using a lumbar puncture needle.
Prior to administration, remove the plastic cap and attach a needle to the syringe, for the purpose of withdrawing QALSODY from the vial. Insert the needle into the vial through the center of the overseal and withdraw the required dose of 15 mL (equivalent to 100 mg) from the vial.
Do not dilute QALSODY.
External filters are not required.
Administer QALSODY using a lumbar puncture needle as an intrathecal bolus injection over 1 to 3 minutes.
QALSODY contains no preservatives. Once drawn into the syringe, the solution should be administered immediately (within 4 hours of removal from the vial) at room temperature; otherwise, it must be discarded.
Any unused contents of the single-dose vial should be discarded.
How to take Tofersen — instructions & advice from the label
Myelitis and/or Radiculitis
Inform patients and caregivers that QALSODY could cause myelitis and radiculitis. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with these adverse reactions develop .
Papilledema and Elevated Intracranial Pressure
Inform patients and caregivers that QALSODY could cause papilledema and elevated intracranial pressure. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with these adverse reactions develop .
Aseptic Meningitis
Inform patients and caregivers that QALSODY could cause aseptic meningitis. Instruct patients and caregivers to contact their healthcare provider if symptoms consistent with meningitis develop .
57294-02
Manufactured by:Biogen MA Inc.Cambridge, MA 02142
QALSODY is a registered trademark of Biogen MA Inc.© Biogen Inc.
Warnings & precautions
Do not take this medicine if: None.
Serious adverse reactions of myelitis and radiculitis have been reported in patients treated with QALSODY. Eight patients treated with QALSODY experienced myelitis or radiculitis in the clinical studies. Two patients discontinued treatment with QALSODY and required symptomatic management with full resolution of symptoms. In the remaining 6 patients, symptoms resolved without discontinuation of QALSODY. If symptoms consistent with myelitis or radiculitis develop, diagnostic workup and treatment should be initiated according to the standard of care. Management may require interruption or discontinuation of QALSODY.
Serious adverse reactions of papilledema and elevated intracranial pressure have been reported in patients treated with QALSODY. Four patients developed elevated intracranial pressure and/or papilledema. All patients received treatment with standard of care with resolution of symptoms, and no events led to discontinuation of QALSODY. If symptoms consistent with papilledema or elevated intracranial pressure develop, diagnostic workup and treatment should be initiated according to the standard of care.
Serious adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) have been reported in patients treated with QALSODY. One patient experienced a serious adverse reaction of chemical meningitis, which led to discontinuation of QALSODY. One patient experienced a serious adverse reaction of aseptic meningitis, which did not lead to discontinuation of QALSODY. In addition, nonserious adverse drug reactions of CSF white blood cell increased, and CSF protein increased have also been reported with QALSODY . If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.
Tofersen side effects
The following clinically significant adverse reactions are discussed elsewhere in the labeling:
Myelitis and/or Radiculitis
Papilledema and Elevated Intracranial Pressure
Aseptic Meningitis
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of QALSODY cannot be directly compared to rates in clinical trials of other drugs and may not reflect the rates observed in practice.
The safety of QALSODY 100 mg was evaluated in 147 patients with SOD1-ALS. The median patient exposure was 199.7 weeks (range from 4 to 321 weeks). QALSODY was evaluated in the placebo-controlled Study 1 and in the open label extension Study 2. In Study 1 Part C, approximately 43% were female; 57% were male; 64% were White and 8% were Asian. The mean age at entry in Study 1 Part C was 49.8 years (range from 23 to 78 years).
The most common adverse reactions (≥ 10% of patients treated with QALSODY and greater than placebo) were pain, fatigue, arthralgia, CSF white blood cell increased, and myalgia. Table 1 shows the common adverse reactions that occurred in at least 5% of patients treated with QALSODY and at a 5% or higher frequency than placebo.
‡‡ Pain includes preferred terms of pain, back pain, and pain in extremity.
* CSF white blood cell increased includes preferred terms of CSF white blood cell increased and pleocytosis. …
About this medicine
Tofersen, an antisense oligonucleotide, is a 20-base residue (20-mer) 5-10-5 MOE gapmer mixed backbone oligonucleotide. Of the nineteen internucleotide linkages, fifteen are 3′-O to 5′-O phosphorothioate diesters, and four are 3′-O to 5′-O phosphate diesters. Ten of the twenty sugar residues are 2-deoxy-D-ribose and the remainder are 2′-O-(2-methoxyethyl)-D-ribose (MOE). The residues are arranged so that there are five MOE nucleosides at the 5′ and 3′-ends of the molecule flanking a gap of ten 2′-deoxynucleosides. The cytosine and uridine bases are methylated at the 5-position. The structural formula is:
Figure 1: Structural Formula for Tofersen
The molecular formula is C230 H317 N72 O123 P19 S15 and the molecular weight is 7127.86 atomic mass units (amu).
QALSODY is supplied as a sterile, preservative-free, clear, and colorless to slightly yellow solution in a Type I glass vial to be administered by intrathecal administration. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 81356b45-1cb7-4eef-88ea-e44cc18b47c5. Read the full official label on DailyMed.